Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Explore Summit Therapeutics' stock performance and financial health amid ivonescimab concerns, and learn how to strategically ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.